These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 38277302)

  • 1. Working Memory Training Responsiveness in Parkinson's Disease Is Not Determined by Cortical Thickness or White Matter Lesions.
    Giehl K; Theis H; Ophey A; Hammes J; Reker P; Eggers C; Fink GR; Kalbe E; van Eimeren T
    J Parkinsons Dis; 2024; 14(2):347-351. PubMed ID: 38277302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gray and White Matter Contributions to Cognitive Frontostriatal Deficits in Non-Demented Parkinson's Disease.
    Price CC; Tanner J; Nguyen PT; Schwab NA; Mitchell S; Slonena E; Brumback B; Okun MS; Mareci TH; Bowers D
    PLoS One; 2016; 11(1):e0147332. PubMed ID: 26784744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential spatial distribution of white matter lesions in Parkinson's and Alzheimer's diseases and cognitive sequelae.
    Grey MT; Mitterová K; Gajdoš M; Uher R; Klobušiaková P; Rektorová I; Rektor I
    J Neural Transm (Vienna); 2022 Aug; 129(8):1023-1030. PubMed ID: 35819634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Statistically Defined Parkinson's Disease Executive and Memory Cognitive Phenotypes: Demographic, Behavioral, and Structural Neuroimaging Comparisons.
    Crowley SJ; Banan G; Amin M; Tanner JJ; Hizel L; Nguyen P; Brumback B; Rodriguez K; McFarland N; Bowers D; Ding M; Mareci TA; Price CC
    J Parkinsons Dis; 2021; 11(1):283-297. PubMed ID: 33216042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modifiable vascular risk factors, white matter disease and cognition in early Parkinson's disease.
    Chahine LM; Dos Santos C; Fullard M; Scordia C; Weintraub D; Erus G; Rosenthal L; Davatzikos C; McMillan CT
    Eur J Neurol; 2019 Feb; 26(2):246-e18. PubMed ID: 30169897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Visual Dysfunction Predicts Cognitive Impairment and White Matter Degeneration in Parkinson's Disease.
    Zarkali A; McColgan P; Leyland LA; Lees AJ; Weil RS
    Mov Disord; 2021 May; 36(5):1191-1202. PubMed ID: 33421201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of diabetes mellitus on longitudinal atrophy and cognition in Parkinson's disease.
    Ong M; Foo H; Chander RJ; Wen MC; Au WL; Sitoh YY; Tan L; Kandiah N
    J Neurol Sci; 2017 Jun; 377():122-126. PubMed ID: 28477681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting Working Memory Training Responsiveness in Parkinson's Disease: Both "System Hardware" and Room for Improvement Are Needed.
    Ophey A; Rehberg S; Giehl K; Eggers C; Reker P; van Eimeren T; Kalbe E
    Neurorehabil Neural Repair; 2021 Feb; 35(2):117-130. PubMed ID: 33410387
    [No Abstract]   [Full Text] [Related]  

  • 9. Gray and white matter imaging: A biomarker for cognitive impairment in early Parkinson's disease?
    Duncan GW; Firbank MJ; Yarnall AJ; Khoo TK; Brooks DJ; Barker RA; Burn DJ; O'Brien JT
    Mov Disord; 2016 Jan; 31(1):103-10. PubMed ID: 26202802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Marked brain asymmetry with intact cognitive functioning in idiopathic Parkinson's disease: a longitudinal analysis.
    Tanner JJ; Levy SA; Schwab NA; Hizel LP; Nguyen PT; Okun MS; Price CC
    Clin Neuropsychol; 2017 Apr; 31(3):654-675. PubMed ID: 27813459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. White matter hyperintensities are not associated with cognitive decline in early Parkinson's disease - The DeNoPa cohort.
    Hanning U; Teuber A; Lang E; Trenkwalder C; Mollenhauer B; Minnerup H
    Parkinsonism Relat Disord; 2019 Dec; 69():61-67. PubMed ID: 31678722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. White matter hyperintensities are linked to future cognitive decline in de novo Parkinson's disease patients.
    Dadar M; Zeighami Y; Yau Y; Fereshtehnejad SM; Maranzano J; Postuma RB; Dagher A; Collins DL
    Neuroimage Clin; 2018; 20():892-900. PubMed ID: 30292088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tracking Cortical Changes Throughout Cognitive Decline in Parkinson's Disease.
    Filippi M; Canu E; Donzuso G; Stojkovic T; Basaia S; Stankovic I; Tomic A; Markovic V; Petrovic I; Stefanova E; Kostic VS; Agosta F
    Mov Disord; 2020 Nov; 35(11):1987-1998. PubMed ID: 32886420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Association of age-related white matter hyperintensity with brain atrophy and cognitive impairment in patients with Parkinson's disease].
    Chen HM; Zhang MM; Wang YL
    Zhonghua Yi Xue Za Zhi; 2020 Nov; 100(43):3397-3401. PubMed ID: 33238668
    [No Abstract]   [Full Text] [Related]  

  • 15. Episodic memory decline in Parkinson' s disease: relation with white matter hyperintense lesions and influence of quantification method.
    Dunet V; Fartaria MJ; Deverdun J; Le Bars E; Maury F; Castelnovo G; Kober T; Cuadra MB; Geny C; Marechal B; de Champfleur NM
    Brain Imaging Behav; 2019 Jun; 13(3):810-818. PubMed ID: 29948903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. White Matter Lesions in Mild Cognitive Impairment and Idiopathic Parkinson's Disease: Multimodal Advanced MRI and Cognitive Associations.
    Rane S; Owen J; Hippe DS; Cholerton B; Zabetian CP; Montine T; Grabowski TJ
    J Neuroimaging; 2020 Nov; 30(6):843-850. PubMed ID: 32937003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The association of cognitive impairment with gray matter atrophy and cortical lesion load in clinically isolated syndrome.
    Diker S; Has AC; Kurne A; Göçmen R; Oğuz KK; Karabudak R
    Mult Scler Relat Disord; 2016 Nov; 10():14-21. PubMed ID: 27919482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longitudinal White Matter Damage Evolution in Parkinson's Disease.
    Scamarcia PG; Agosta F; Spinelli EG; Basaia S; Stojković T; Stankovic I; Sarasso E; Canu E; Markovic V; Petrović I; Stefanova E; Pagani E; Kostic VS; Filippi M
    Mov Disord; 2022 Feb; 37(2):315-324. PubMed ID: 34806799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic oxidative stress and cognitive function in Parkinson's disease with different PWMH or DWMH lesions.
    Chang TC; Chen YC; Huang YC; Lin WC; Lu CH
    BMC Neurol; 2021 Jan; 21(1):16. PubMed ID: 33430806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The contribution of white matter lesions (WML) to Parkinson's disease cognitive impairment symptoms: A critical review of the literature.
    Veselý B; Rektor I
    Parkinsonism Relat Disord; 2016 Jan; 22 Suppl 1():S166-70. PubMed ID: 26391185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.